Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.
Orthofix (OFIX) Launches Limb Lengthening System in US & UK
by Zacks Equity Research
With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.
Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.
LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.
Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.
HEXO Soars: Stock Adds 7.9% in Session
by Zacks Equity Research
HEXO saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Here's Why Abbott (ABT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe
by Zacks Equity Research
Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.
Boston Scientific (BSX) Hurt by Product Recall, Conversion
by Zacks Equity Research
Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.
Hill-Rom's (HRC) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Hill-Rom's (HRC) first-quarter fiscal 2021 revenue climbed 8.2% year over year to $741.1 million.
Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results reflect strong segmental performance.
Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q1
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows
by Zacks Equity Research
Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.
Change Healthcare (CHNG) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance in the Network Solutions segment.
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.
AmerisourceBergen (ABC) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.
Align Technology (ALGN) Beats on Q4 Earnings, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid sales across geographies despite the pandemic-led business challenges.
Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.